Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBT (2016 - 2025)

Historic EBT for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$16.9 million.

  • Northwest Biotherapeutics' EBT fell 35.54% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 541.68%. This contributed to the annual value of -$74.3 million for FY2024, which is 2226.54% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported EBT of -$16.9 million as of Q3 2025, which was down 35.54% from -$16.6 million recorded in Q2 2025.
  • Northwest Biotherapeutics' EBT's 5-year high stood at -$11.7 million during Q3 2021, with a 5-year trough of -$22.5 million in Q2 2022.
  • In the last 5 years, Northwest Biotherapeutics' EBT had a median value of -$16.9 million in 2024 and averaged -$16.8 million.
  • Data for Northwest Biotherapeutics' EBT shows a peak YoY increase of 7818.48% (in 2021) and a maximum YoY decrease of 14848.66% (in 2021) over the last 5 years.
  • Northwest Biotherapeutics' EBT (Quarter) stood at -$11.8 million in 2021, then tumbled by 64.0% to -$19.4 million in 2022, then rose by 15.54% to -$16.4 million in 2023, then dropped by 28.09% to -$21.0 million in 2024, then increased by 19.28% to -$16.9 million in 2025.
  • Its EBT stands at -$16.9 million for Q3 2025, versus -$16.6 million for Q2 2025 and -$18.9 million for Q1 2025.